- METALLOENZYME INHIBITOR COMPOUNDS
-
Provided are compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.
- -
-
-
- PROTEIN KINASE INHIBITORS
-
A compound of formula (I), wherein R3, R4, G, B, M, and Z are as defined in the claims, and pharmaceutically acceptable salts thereof are disclosed. The compounds of formula (I) possess utility as FGFR inhibitors and are useful in the treatment of a condition, where FGFR kinase inhibition is desired, such as cancer.
- -
-
-
- PROTEIN KINASE INHIBITORS
-
A compound of formula (I), wherein R3, R4, G, B, M, and Z are as defined in the claims, and pharmaceutically acceptable salts thereof are disclosed. The compounds of formula (I) possess utility as FGFR inhibitors and are useful in the treatment of a condition, where FGFR kinase inhibition is desired, such as cancer.
- -
-
-
- NITROHETEROARYL-CONTAINING RIFAMYCIN DERIVATIVES
-
Substituted rifamycin derivatives in which a nitroimidazole, nitrothiazole or nitrofuran pharmacophore is covalently bonded to a rifamycin, methods of using the rifamycin derivatives, and pharmaceutical compositions containing the rifamycin derivatives are disclosed. Methods of synthesizing these substituted rifamycin derivatives are also disclosed. The rifamycin derivatives possess antibacterial activity, and are effective against a number of human and veterinary pathogens in the treatment of bacterial diseases.
- -
-
Page/Page column 60
(2010/11/29)
-
- NK1 and NK3 antagonists
-
The invention is to a compound exhibiting neurokinin inhibitory properties, a pharmaceutical composition comprising same and a method of treatment for neurokinin-mediated conditions.
- -
-
Page/Page column 27
(2010/02/14)
-
- CARBOXYSUBSTITUTED CYCLIC CARBOXAMIDE DERIVATIVES
-
The present invention relates to novel carboxy substituted cyclic carboxamide derivatives of formula (1), STR1 and stereoisomers and pharmaceutically acceptable salts thereof and their use as tachykinin receptor antagonists. Such antagonists are useful in the treatment of tachykinin-mediated diseases and conditions disclosed herein including: asthma, coughs and bronchitis.
- -
-
-
- 4-METHOXY-5-METHYL-PYRAN-3-OL NATURAL PRODUCTS AND DERIVATIVES THEREOF
-
Novel antibiotic substances, including novel natural products, having the general formula wherein R1 and R2 are as defined herein, are disclosed. These compounds have been found to be cytochrome P450 inhibitors.
- -
-
-